Originally published In Press as doi:10.1074/jbc.M204135200 on August 8, 2002
J. Biol. Chem., Vol. 277, Issue 46, 44339-44346, November 15, 2002
Two Distinct Domains of Protein 4.1 Critical
for Assembly of Functional Nuclei in Vitro*
Sharon Wald
Krauss
§,
Rebecca
Heald¶,
Gloria
Lee
,
Wataru
Nunomura
,
J. Aura
Gimm
,
Narla
Mohandas
, and
Joel Anne
Chasis
From the
Department of Subcellular Structure, Life
Sciences Division, University of California, Lawrence Berkeley National
Laboratory, Berkeley, California 94720, the ¶ Department of
Molecular and Cell Biology, Division of Cell and Developmental
Biology, University of California, Berkeley, California 94720, and the
Department of Biochemistry, School of Medicine, Tokyo
Women's Medical University, Shinjuku, Tokyo 162-8666, Japan
Received for publication, April 29, 2002, and in revised form, August 5, 2002
 |
ABSTRACT |
Protein 4.1R, a multifunctional structural
protein, acts as an adaptor in mature red cell membrane skeletons
linking spectrin-actin complexes to plasma membrane-associated
proteins. In nucleated cells protein 4.1 is not associated exclusively
with plasma membrane but is also detected at several important
subcellular locations crucial for cell division. To identify 4.1 domains having critical functions in nuclear assembly, 4.1 domain
peptides were added to Xenopus egg extract nuclear
reconstitution reactions. Morphologically disorganized, replication
deficient nuclei assembled when spectrin-actin-binding domain or
NuMA-binding C-terminal domain peptides were present. However, control
variant spectrin-actin-binding domain peptides incapable of binding
actin or mutant C-terminal domain peptides with reduced NuMA binding
had no deleterious effects on nuclear reconstitution. To test whether
4.1 is required for proper nuclear assembly, 4.1 isoforms were depleted
with spectrin-actin binding or C-terminal domain-specific antibodies.
Nuclei assembled in the depleted extracts were deranged. However,
nuclear assembly could be rescued by the addition of recombinant 4.1R.
Our data establish that protein 4.1 is essential for nuclear assembly
and identify two distinct 4.1 domains, initially characterized in cytoskeletal interactions, that have crucial and versatile functions in
nuclear assembly.
 |
INTRODUCTION |
Protein 4.1R was classically defined as an ~80-kDa cytoskeletal
protein of mature human red cells crucial for maintaining erythrocyte
shape and mechanical stability (for reviews see Refs. 1 and 2). In the
red cell membrane skeleton, protein 4.1R stabilizes junctional
interactions in the spectrin-actin lattice. It also binds to
cytoplasmic domains of several transmembrane proteins such as
glycophorin C and Band 3. Thus 4.1R provides linkage between the red
cell cytoskeletal network and the overlying plasma membrane. Defects in
protein 4.1 are associated with hereditary red cell elliptocytosis
characterized by membrane fragmentation (as reviewed in Ref. 3).
In nucleated cells, however, protein 4.1 is not exclusively associated
with the plasma membrane-associated cytoskeleton. Protein 4.1 epitopes
are detected at several important subcellular locations crucial to cell
division (4-8). In particular, protein 4.1 is at intranuclear sites in
the nuclear matrix/scaffold (6, 7), at centrosomes (8), at mitotic
spindle poles, in perichromosomal regions (7, 9), and at the midbody at
telophase (7). The complex localization patterns of 4.1 in nucleated
cells may reflect that although red cells contain predominantly one
80-kDa isoform, nucleated cells generally express multiple 4.1 isoforms generated via alternative splicing, posttranslational modifications, and expression of multiple related genes (10-14).
Analysis of 4.1R has revealed several functional domains important for
its interactions in red cells, but the potential roles of these domains
in nucleated cells have not been completely determined. A 4.1 domain
that specifically interacts to form ternary complexes with spectrin and
actin was mapped to exons 16,17 (spectrin-actin-binding domain,
SABD)1 (15-21) (see Fig.
1A). The 4.1 30-kDa/FERM (4.1-ezrin-radixin-moesin) domain (beginning within exon 4 and ending within exon 12; see Fig.
1A) was shown to interact with membrane proteins such as glycophorin C, anion exchanger Band 3, a membrane-associated guanylate kinase (MAGUK/p55), a cell surface receptor promoting tumor growth (CD44), ICAM-2, a chloride channel regulator (pICln), and calmodulin (1, 22-25). In nucleated cells, both the FERM domain and the SABD
interact with importin
for nuclear import of protein 4.1 (26).
Additionally, exons 20,21 in the 4.1 C-terminal domain (CTD; see Fig.
1A) recently were shown to interact with the nuclear mitotic
apparatus protein NuMA (27), ZO2 (28) and immunophilin-binding protein
FKBP13 (29). Thus in nucleated cells these 4.1 functional domains may
serve as important linkers to actin structures, membrane-associated proteins, or microtubule-based structures.
Here we report that 4.1 is essential for proper assembly of
nuclei, involving interactions of two distinct 4.1 domains. We have
used Xenopus egg extracts, a very powerful in
vitro experimental system that mimics in vivo events
such as assembly of nuclei and spindles, semiconservative DNA
replication, and cell cycle regulation (30-35). When incubated with
interphasic Xenopus egg extract, demembranated sperm DNA
decondenses and recruits chromosomal and scaffold proteins to form
mature nuclei containing a double membrane with pores, nuclear lamina,
and a perinuclear centrosome derived from the sperm basal body. The
reconstituted nuclei replicate DNA and import proteins bearing
appropriate nuclear localization signals.
Using this system we established that 4.1 is essential for nuclear
assembly. Depletion of 4.1 from extracts prevents nuclear assembly,
which is restored by addition of recombinant 4.1R. We identified
two 4.1R domains critical to nuclear assembly in assays utilizing
dominant negative peptides corresponding to protein 4.1 domains. This
strategy has several advantages because peptides can be added in
controlled concentrations to reactions, may mediate effects by
competitive binding to 4.1 substrates, and may circumvent issues of
steric hindrance in antibody inhibition experiments by antibodies bound
to endogenous 4.1 proteins. One 4.1 domain, the SABD, appears to
require interaction with actin to have a critical role in nuclear
assembly. The other domain critical for nuclear assembly, the CTD, was
shown previously to interact with NuMA (27). Our data demonstrate that
protein 4.1 is essential for proper assembly of nuclei and identify two
distinct 4.1 domains, initially characterized in cytoskeletal
interactions, with crucial and versatile functions in nuclear assembly.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Expression vectors for His6 fusion
peptides were either pMW172 (the gift of Dr. M. Way, EMBL, Heidelberg)
or pET 28 (Novagen). The NuMA Tail I construct and antibody
L046F7 against Xenopus lamin were very generous
gifts of Dr. A. Merdes (University of Edinburgh, Edinburgh,
UK). IgGs against 4.1R SABD and 4.1R CTD have been described (7). The
antibodies from commercial sources were
-Sm (Y12; Neomarkers),
monoclonal antibody 414 against nuclear pore complex protein
(Babco),
-BrdUrd (BD Biosciences),
-His6 epitope tag (CLONTECH), and fluorescent secondary
antibodies (Molecular Probes). BrdUrd was from Sigma, and protein A
Affiprep was from Bio-Rad.
Xenopus Extracts and Nuclear Assembly Reactions--
10,000 × g cytoplasmic Xenopus egg extracts were
prepared as described (36) and made interphasic with 400 µM Ca2+. For nuclear assembly, demembranated
Xenopus sperm were added to 20 µl of egg extract on ice
with 0.2 mg/ml Texas Red-labeled bovine brain tubulin (37) as
indicated, and the mixtures were incubated at 20 °C for 40-60 min.
Assays with His6 peptides (1-8 µg) were preincubated on
ice 10 min and then incubated at 20 °C. The reactions diluted with
BRB80 (80 mM PIPES, 2 mM MgCl2, 1 mM EGTA, pH 6.8) containing 15% glycerol and 1% Triton
X-100 were spun through 25% glycerol-BRB80 cushions onto coverslips.
For Western blots, extract first was cleared of nonspecific aggregates by centrifugation at 1500 × g prior to incubation with
sperm. After nuclear assembly, the reactions were diluted, and the
nuclei were pelleted through cushions by centrifugation at 1500 × g in Eppendorf tubes. The nuclear pellets were rinsed with
BRB80 and dissolved in SDS-PAGE loading buffer. Aliquots of resuspended pellets fixed on coverslips produced only intranuclear
immunofluorescence when probed with 4.1 antibodies. Although a range of
1-8 µg was tested for each peptide, the data presented are from
experiments using 8 µg of the indicated peptide.
Indirect Immunofluorescence--
In vitro assembled
nuclei on coverslips were fixed in
20 °C methanol and probed by
immunofluorescence as described (38). The concentrations of primary
antibodies were: SABD IgG, 5 µg/ml; CTD IgG, 10 µg/ml; monoclonal
antibody 414, 1:2500 dilution; L046F7, 1/10 dilution; and
Y12, 1 µg/ml. Secondary fluorescent antibodies were used at a 1:100
dilution. The samples probed without primary antibody or with equal
amounts of control nonimmune IgG or sera showed no fluorescent
patterns. Images were captured using a Nikon Eclipse E600 microscope
equipped with a CCD camera and processed using Adobe Photoshop.
Expression and Purification of His6-tagged
Proteins--
Protein 4.1-related peptides were expressed as
His6 fusion proteins in BL21/DE3, pLysS grown at 30 °C
and induced for 3 h with 1 mM
isopropyl-1-thio-
-D-galactopyranoside.
His6-tagged peptides were purified by nickel-agarose
chromatography (Qiagen), then dialyzed into XB buffer (0.1 M KCl, 1 mM MgCl2, 0.1 M CaCl2, 50 mM sucrose, and 10 mM K-HEPES, pH 7.7), and analyzed by Western blot for both
protein 4.1 and His6 tag epitopes.
In Vitro Protein Binding Assay Using Resonant Mirror
Detection--
Interactions between NuMA Tail I peptide and 4.1R CTD
and CTDmut3V were measured using the IAsysTm system
(Affinity Sensors) and FASTfitTM software as detailed (22,
39). Purified peptides were dialyzed into phosphate-buffered saline
prior to binding reactions at 25 °C.
BrdUrd Labeling of Nuclei Assembled in Vitro--
The
nuclei were assembled in interphasic Xenopus egg extract
made 20 µM in BrdUrd and fixed in cold methanol. DNA was
denatured in 2 N HCl/0.5% Triton X-100 and then
neutralized with 0.1 M borate, pH 8.5, and the coverslips
were probed with 10 µg/ml
BrdUrd for indirect immunofluorescence.
Immunodepletion and Rescue--
For depletion of 4.1 from
Xenopus extracts, protein G-coupled magnetic beads (Dynal)
from 100 µl of slurry were mixed with 15 µg of 4.1R SABD or CTD
IgGs or nonimmune rabbit IgG for 1 h at 4 °C; the beads washed
twice with 0.1 M sodium phosphate buffer, pH 7.0 (57.7%
Na2HPO4 and 42.3%
NaH2PO4, v/v) and three times with XB buffer
and then divided into three aliquots. The extract (100 µl) was
successively depleted three times by rotation with IgG-coupled beads at
4 °C for 1 h, the beads were collected magnetically, and the
extract was used for nuclear assembly and Western blotting. Extract
depletion was determined by densitometry of Western blots using an
Alpha Imager 2200 and software. In rescue experiments, 1-9 µg of
purified bacterially expressed 80-kDa 4.1R was added to 20-µl
reactions and incubated on ice for 10 min prior to initiation of
nuclear assembly. The reactions in three independent experiments were
sampled during 30-90 min of incubation.
 |
RESULTS |
Localization of 4.1 in Nuclei Reconstituted in Xenopus Egg Extracts
Is Similar to That in Mammalian Cells--
To dissect protein 4.1 function in nuclear assembly, we performed experiments using
Xenopus egg extracts. Our previous work in cultured
mammalian cells established that nuclear protein 4.1R epitopes are
distributed throughout non-nucleolar nuclear domains (7). Comparisons
of regions of Xenopus 4.1 sequence with those of mammalian
family members revealed strong conservation in the SABD as well as the
CTD (Fig. 1B). In studies
exploring the evolutionary conservation of 4.1 function, a recombinant
glutathione S-transferase fusion protein encoding the
Xenopus SABD specifically bound to and mechanically
stabilized 4.1-deficient human erythrocyte membranes (40), providing a
precedent of functional domain interchange between Xenopus
4.1 SABD and mammalian 4.1R.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1.
Domain organization of protein 4.1 and amino
acid sequences of 4.1 family members in two domains. A,
a schematic map of 4.1R indicating functional interacting domains. The
exon numbers appear below the bar with
asterisks indicating alternatively spliced exons. The
arrows indicate translation initiation sites. Isoforms
initiated at AUG1 include the N-terminal extension (exons 2'-4). The
membrane binding 30-kDa/FERM domain extends from exons 4 to 12. In this
report, SABD refers to amino acid sequences from exons 16, partial 17, whereas the CTD denotes peptides from exons 20,21. B,
sequences of regions related to the SABD and to the CTD of red cell
protein 4.1. The domains of 4.1 family members shown are: X,
Xenopus (40); G, generally expressed (29, 76);
B, brain (77); N, neuronal (78). The accession
numbers are: 4.1R, L00919; 4.1G, AF044312; 4.1B, AF152247; and 4.1N,
AF061283. The regions of amino acid homology of Xenopus 4.1 to other family members are boxed.
|
|
Initially we verified that nuclei of cultured Xenopus
fibroblasts as well as Xenopus nuclei assembled in
vitro contained 4.1 epitopes. In vitro assembled nuclei
stained with
CTD produced a diffuse intranuclear immunofluorescent
pattern, whereas
SABD staining revealed a diffuse pattern as well as
larger intranuclear circular or toroidal structures (Fig.
2A). Sperm basal bodies, precursors to mitotic spindle poles, also displayed 4.1 epitopes in
Xenopus (Fig. 2A) as well as in murine and
porcine samples (41). To further explore the nature of the nuclear
toroidal structures detected with
SABD, reconstituted nuclei were
probed with a variety of antibodies against splicing factors because 4.1 epitopes previously were observed to colocalize with splicing factors (7, 42, 43). Double label experiments revealed a strong
coincidence of immunofluorescent signals for Sm antigens (monoclonal
Y12) with SABD epitopes in intranuclear toroids along with additional
coincidence in some of the smaller more diffuse intranuclear foci (Fig.
2B). In confocal sections, larger toroidal structures in
Xenopus nuclei appeared to be composed of multiple smaller
domains (Fig. 2A), consistent with mammalian cells (44). Thus Xenopus extracts appear to be a valuable and
appropriate experimental system for deciphering 4.1 functions.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Protein 4.1 epitopes in Xenopus
sperm and nuclei assembled in vitro detected by
immunofluorescent microscopy. Localization of DNA was by DAPI.
A, left, protein 4.1 signals (green)
in sperm at the basal body region, adjacent to the sperm pronuclear
chromatin (blue). Middle, nuclear SABD and CTD
signals (green) in Xenopus nuclei assembled
in vitro. Right, a confocal micrograph of
SABD-stained toroids at the midsection of a nucleus. Bar,
10 µm. B, double label immunofluorescent microscopy of a
representative Xenopus nucleus assembled in vitro
and stained with SABD (green) and Sm (red).
The yellow signals in the merged image indicate
colocalization of SABD and Sm epitopes.
|
|
Dominant Negative 4.1 Peptides Distort Nuclear Formation in
Vitro--
To dissect 4.1 function in nuclei, we added bacterially
expressed peptides encoding 4.1 domains to nuclear assembly reactions and then observed and quantified the morphological characteristics of
the resulting structures. For these experiments,
His6-tagged peptides were constructed based on their
relationship to either exons 16,17 (amino acids 644-705) in the 4.1R
SABD or exons 20,21 (amino acids 800-858) of the 4.1R CTD (Fig.
3), because these domains already have
important defined functions and are highly conserved between frog and
mammals (Fig. 1B). For purposes of simplicity, these domains
will be referred to as SABD or CTD peptides. As controls for the 4.1R
SABD peptide, we used a variant 4.1N SABD peptide with low amino acid
sequence homology to the 4.1R peptide (Fig. 3). As a second control, we
expressed a 4.1R SABD
NF peptide with a deletion of two amino acids
within its actin-binding domain. This mutant SABD cannot bind actin but
retains spectrin binding (45). Importantly, both of these control
peptides are incapable of forming ternary complexes with spectrin and
actin (45). As control for the 4.1R CTD peptide, a peptide was
engineered containing the 4.1R CTD sequence, except that three valines
were mutated to alanines (Fig. 3) based on a preliminary report that these residues are part of the 4.1R NuMA-binding site (46). In
experiments measuring the relative affinities of 4.1R to NuMA Tail I
peptides (47) containing the 4.1 binding site (9), we determined that
the binding affinity of the mutated 4.1R CTD peptide is decreased about
60-fold compared with the unmutated peptide sequence (Table
I). Interestingly, the dissociation
constants of the CTD peptide and the 80-kDa red cell 4.1 for Tail I are similar, implying that other 4.1 domains do not significantly contribute to NuMA Tail I
binding.2

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
Amino acid sequences of expressed peptides
related to 4.1 SABD and CTD that were added to in vitro
nuclear assembly reactions. The 4.1N 16,17 peptide encodes a
region corresponding to 4.1R SABD (exons 16,17), but it is apparent
from the homology boxes that very few amino acids are in common with
4.1R. The 4.1R 16,17 NF has amino acids identical to 4.1R except for
the deletion of an asparagine and a phenylalanine in exon 17 (indicated
by asterisks). The 4.1R CTD peptide encodes exons 20,21 and
the 4.1R 20,21mut3V peptide has an identical sequence except that
three valines have been mutated to alanines
(underlined).
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Dissociation constants of protein interactions measured by resonant
mirror detection
The NuMA Tail 1 construct (amino acids 1719-1993; Ref. 47) encodes the
4.1 binding site, and exons 20,21 of 4.1R interacts with NuMA (27). The
amino acid sequences of 4.1R 20,21 and 4.1R 20,21 mut3V are presented
in Fig. 3. NuMA Tail I (1.3 mM) was introduced into
aminosilane curvettes with either immobilized 4.1R 20,21 or 4.1R 20,21 mut3V peptides. The binding data indicate that mutation of three
alanines to valine residues in 4.1R 20,21 mut3V decreased its affinity
for NuMA Tail I about 60-fold.
|
|
The addition of SABD peptides produced nuclei that were smaller,
multilobed, and surrounded by disarrayed microtubules relative to
control nuclei (Fig. 4A,
top row). Both nuclear membrane pores and the underlying
lamin network were disorganized in nuclear structures assembled in
reactions containing the 4.1R SABD peptides (Fig. 4A,
middle and bottom rows). By contrast, a deletion
mutant in the 4.1R SABD (
NF) did not affect nuclear assembly because the nuclei were normal in size, had continuous rims of pores and lamin,
and displayed microtubule arrays similar to control nuclei (Fig.
4A). A variant SABD from 4.1N (neuronal) had only a very weak effect, suggesting that this domain in a 4.1N isoform does not
have a similar function to that of 4.1R SABD in the nucleus. In fact,
in extracts of murine fibroblast nuclei we did not detect 4.1N by
Western blot analysis, consistent with our observations that 4.1N
peptides had little effect on in vitro nuclear assembly in
Xenopus egg extracts. Quantitation shows that dominant
negative effects of 4.1R SABD peptides on both proper nuclear assembly and efficiency of assembly are profound and quite sequence-specific (Fig. 4B). Thus the 4.1 SABD, capable of forming ternary
complexes with spectrin and actin, is critical for proper assembly of
nuclei in vitro.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of 4.1 peptides on assembly of nuclei
in vitro in Xenopus interphasic egg
extracts. A, the products of assembly reactions with
the indicated His6 peptides were visualized by
immunofluorescence. The reactions were spiked with fluorescent bovine
tubulin (top; red) or probed with monoclonal
antibody 414 against nuclear pores (middle; red)
or antibody L046F7 against lamin (bottom;
red). DNA (blue) was stained by DAPI. All of the
images within the horizontal register are at equal magnification.
Bar, 10 µm. B, quantitation of nuclear assembly
perturbation by 4.1R SABD and 4.1R CTD peptides. Control reactions
included buffer alone, variant 4.1N SABD peptides, or 4.1R SABD NF
peptides. The total number of structures counted is indicated below.
The data from reactions containing 4.1R CTDmut3V peptides are not
presented because perturbation was less dramatic and thus more
difficult to accurately score.
|
|
A second 4.1 domain, the CTD, was also critical for assembly of normal
nuclei. CTD peptides encoding exons 20,21 strongly perturbed formation
of nuclei qualitatively and quantitatively (Fig. 4); microtubules,
pores, and lamina were disorganized relative to control nuclei.
However, the 4.1R CTD peptide with three mutated valines and decreased
affinity for binding NuMA (Table I) produced nuclei with morphologies
intermediate between control and aberrant nuclei assembled in the
presence of either 4.1R SABD or 4.1R CTD peptides. Nuclei isolated from
these reactions were ovoid, although smaller than controls, had
relatively normal distributions of pores and lamin, but displayed
miniature centrosomal asters. Given the strong dominant negative effect
of unmutated 4.1R CTD peptides on nuclear assembly (Fig. 4), this
observation implies that an interaction with NuMA might mediate peptide
effects on nuclear reconstitution. In support of this possibility, we
observed that NuMA Tail I peptides containing sequences capable of
binding 4.1 CTD (Table I) perturbed nuclear assembly reactions (Fig.
5A), producing small
irregularly shaped DNA structures. Furthermore, preincubation of 4.1R
CTD and NuMA Tail I peptides prior to initiation of nuclear assembly
rescued or restored normal nuclear reconstitution relative to the
dominant negative effect produced in reactions containing either
peptide species alone (Fig. 5A). Taken together, these
observations support the hypothesis that 4.1-NuMA interactions may be
critical for nuclear assembly.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 5.
A, rescue of CTD peptide perturbation of
in vitro nuclear assembly. Peptides encoding 4.1R CTD and
NuMA Tail I were preincubated in equimolar amounts before incubation of
assembly reactions. DNA was visualized by DAPI (blue). The
samples containing only 4.1R CTD or NuMA Tail I peptides served as
negative controls. Bar, 10 µm. B, DNA
replication capacity of perturbed nuclei from in vitro
reactions containing 4.1R SABD or 4.1R CTD dominant negative peptides.
BrdUrd incorporation into DNA of control nuclei assembled in
Xenopus egg extract containing BrdUrd was visualized by
fluorescence (BrdUrd, green). The samples with 4.1 peptides
added produced no detectable BrdUrd signals overlapping DNA
(blue) above background or above negative control nuclei
with peptides and BrdUrd omitted. C, analysis of detectable
4.1 epitopes in distorted nuclear structures from reactions with 4.1R
SABD or 4.1R CTD dominant negative peptides. Nuclear structures from
in vitro reactions containing the peptides indicated above
were probed with antibodies specified below (green). DNA was
imaged with DAPI (blue).
|
|
To further analyze the extent of nuclear assembly perturbation produced
by SABD and CTD peptides, we assayed the capacity to replicate DNA. In
extracts supplemented with 20 µM BrdUrd, nucleotide
analogue incorporation into DNA by control nuclei was readily detected
by immunofluorescence, whereas aberrant nuclei from reactions
containing either 4.1R SABD or CTD peptides had no or very low
amounts of detectable BrdUrd (Fig. 5B). Thus in addition to
gross morphological abnormalities observed in nuclear structures formed
in the presence of either 4.1R SABD or 4.1R CTD peptides, these data
demonstrate that the aberrant nuclei are metabolically incapacitated.
To test whether dominant negative effects of SABD or CTD peptides
were due to incorporation of SABD or CTD peptides into abnormal nuclear
structures, we probed isolated assembly reaction products with CTD and
SABD IgGs. We observed that aberrant nuclei had very reduced or no
detectable immunofluorescent signals (Fig. 5C). Thus it
appears that relatively little exogenous peptide was incorporated and
also that endogenous Xenopus 4.1 was displaced from abnormal nuclear structures.
Defective Nuclear Assembly in 4.1-immunodepleted Extracts Can Be
Rescued by Recombinant 4.1R--
To confirm an essential role for 4.1 in nuclear assembly and the importance of the SABD and CTD domains, we
depleted 4.1 from Xenopus egg extracts using 4.1 domain-specific IgGs bound to protein G magnetic beads. Although normal
nuclei assembled in control extracts, a dramatic morphologic disruption
of nuclear assembly was apparent in extracts depleted with either SABD
or CTD IgGs (Fig. 6A). In
general, 80-95% of nuclei from SABD-depleted extracts were small and
irregularly shaped, whereas those from CTD-depleted extracts were
highly condensed and often bean-shaped. By immunofluorescence (Fig.
6B) and by Western blotting (data not shown), aberrant
nuclei from depleted extracts had no detectable SABD or CTD epitopes. Nuclear pore and lamin epitopes were irregularly distributed, similar
to perturbed nuclei assembled in the presence of SABD and CTD peptides
(Fig. 6B). Western blotting showed that Xenopus extracts and isolated nuclei contain protein bands from ~47 to 110 kDa detected by IgGs against 4.1 SABD and CTD (Fig. 6, C and C'), which could be effectively reduced by 50-100%
following three rounds of depletion (Fig. 6C'). Therefore,
even incomplete removal of 4.1 proteins containing SABD and CTD regions
dramatically inhibited nuclear assembly in vitro. Defects in
nuclear reconstitution observed in 4.1-depleted extracts or upon
addition of 4.1 SABD or CTD peptides could be due to functional
disruption of either 4.1 or a 4.1 binding partner essential for nuclear
assembly. To directly test whether 4.1 itself is critical for nuclear
assembly, purified recombinant 80-kDa 4.1R was preincubated with
depleted extracts. Nuclear assembly was completely restored in both
-SABD and
-CTD-depleted extracts, producing regularly shaped
nuclei with decondensed DNA comparable in size with controls (Fig.
6A') and with a normal distribution of pores and lamina
(data not shown). Restoration of normal nuclear assembly by recombinant
80-kDa 4.1R, containing both the SABD and CTD, demonstrates that 4.1 itself is crucial for nuclear assembly.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 6.
Aberrant nuclear assembly in 4.1 depleted
extracts and rescue of defective nuclear assembly by the addition of
recombinant 80-kDa 4.1. A, the products of nuclear assembly
reactions in Xenopus extracts depleted using SABD IgG
( SABD) or CTD IgG ( CTD) relative to nuclei
assembled in control extracts (IgG) were imaged with DAPI
(blue). A', nuclei assembled after the addition
of recombinant 80-kDa 4.1R (+4.1) to depleted extracts. With the
addition of 4.5 µg of 80-kDa 4.1 (4.4 µM), the nuclei
were ~50-80% the size of mock-depleted or control nuclei, whereas
with 9 µg of 80-kDa 4.1 (8.8 µM), the nuclei were
similar in size to controls (as shown). DNA was imaged with DAPI
(blue). B, double label immunofluorescence of
abnormal nuclei assembled in depleted extracts. Epitopes for lamin
(L046F7), nuclear pores (monoclonal antibody 414), SABD, or
CTD (red) were probed in structures assembled in depleted
extracts (DNA, blue). C, Western blot analysis of
Xenopus egg extract and isolated nuclei assembled in
vitro probed with SABD and CTD IgGs. Immunoreactive bands
1 and 3-6 are detected both in nuclei and extract,
whereas bands 2 and 7 are detected in extract
only. The epitopes detected are: bands 1, 2, and
6, SABD and CTD; bands 3-5 and 7, CTD
only. No significant bands were detected when nuclei were probed with
an equal amount of nonimmune IgG or when proteins from mock assembly
reactions without sperm were probed with SABD or CTD IgGs.
C', Western blot analysis of equal amounts of extracts
depleted with SABD or CTD IgGs or incubated with control IgG. In
extracts depleted with SABD IgG, bands 1 and 6 appear fully depleted, whereas band 2 is 52% depleted
relative to a mock depleted (control IgG) lane by densitometry
measurements. In extracts depleted with CTD IgG, band 1 and
bands 5-7 are 72 and 69% depleted, respectively.
Bands 3 and 4 in CTD depleted extracts were too
faint to be accurately measured and thus are estimated to be more than
~70% depleted. The red brackets indicate areas scanned by
densitometry. The arrow (C') indicates a
nonspecific band seen in some experiments.
|
|
 |
DISCUSSION |
Protein 4.1 Is Essential for Nuclear Assembly--
Protein 4.1 is
a multifunctional structural protein with well characterized protein
interactions in mammalian red cells integrating or stabilizing
structural subcomponents of the membrane skeleton with integral
membrane proteins. Previously we reported that in mammalian cells 4.1 epitopes localize to nuclear matrix and centrosomes at interphase and
then become redistributed to the mitotic spindle, perichromatin, and
midbody during the cell cycle. The experiments presented here exploited
the power of in vitro nuclear reconstitution using
Xenopus egg extracts to identify 4.1R peptides that act as
dominant negatives in nuclear assembly reactions and to investigate possible protein 4.1 interactions crucial for proper nuclear assembly. We found that peptides from two distinct 4.1 domains severely compromised the capacity of nuclei to replicate DNA, an end point of
proper nuclear reconstitution. However, morphologic aberrations also
were detected in microtubule, lamina, and nuclear pore
organization. Therefore, the dominant negative effects of the 4.1R
SABD and CTD peptides probably are exerted at early stages of nuclear
formation (48, 49). Our data demonstrate that at least two 4.1R domains contribute to formation of functional nuclei. Interestingly both of
these 4.1R domains are also involved in important protein-protein interactions in cytoplasmic subcellular structures.
The aberrant nuclear structures had little endogenous
Xenopus 4.1 or exogenous 4.1 peptides. This might implicate
either disruption of 4.1 function directly or functional inhibition of
key 4.1 partners, sequestered by 4.1 peptides. For example, replication
defective nuclei are observed when lamin function is perturbed or
absent (50-52). The absence of 4.1 in defective nuclei may indicate a disruption of importin pathways because the SABD contains a nuclear localization signal that binds importin
(26). Compromised import
could have major effects on nuclear assembly, including DNA
decondensation and DNA replication.
In depletion/add-back experiments, markedly abnormal nuclei formed in
depleted extracts, but the addition of purified recombinant 80-kDa 4.1R
protein restored normal nuclear assembly. Thus 4.1R alone was
sufficient for rescue of nuclear assembly, even though extracts were
not entirely devoid of detectable 4.1 by Western blot analysis.
Residual 4.1 in extracts was resistant to complete removal by further
rounds of depletion, perhaps because of denaturation or complexes
rendering 4.1 epitopes inaccessible.
4.1-Actin Binding Capacity Is Necessary for Nuclear
Assembly--
One of the 4.1R dominant negative peptides (SABD)
contains all of the amino acids necessary for binding of spectrin
(1-21 of exon 16 and 27-43 of exon 17) (16, 19, 53, 54) as well as
the binding site for actin (amino acids 19-26 of exon 17) (45). Two
variant SABD peptides, both incapable of forming ternary complexes with
spectrin/actin, did not perturb nuclear assembly in vitro, even though one peptide binds spectrin but not actin. Thus we conclude
that the actin binding capacity of 4.1 SABD is crucial for proper
nuclear assembly.
It is likely that there are multiple binding partners of nuclear 4.1 and actin. Although reports of nuclear actin have long been
controversial, mounting evidence now includes identification of two
nuclear export sequences in actin, characterization of numerous
actin-binding proteins in nuclei, ultrastructural localization of
intranuclear actin, and cross-linking of actin to DNA (reviewed in Ref.
55). Recent direct evidence that the BAF (BRG- or Brm-associated factors) chromatin remodeling complex contains a functional
-actin subunit (56) and that nuclear DNA helicase II binds actin and is detected adjacent to nuclear actin filaments (57) has implicated essential functions for nuclear actin. Additionally, subnuclear localization of actin adjacent to spliceosomes has been reported (58).
Protein 4.1 epitopes are detected at spliceosomes in mammalian cells
(7, 42) and in Xenopus nuclei as reported here. By analogy to 4.1 function as an adaptor within the plasma membrane cytoskeleton, during nuclear assembly 4.1 may act to recruit factors or
modulate multiprotein interactions crucial for proper nuclear formation.
4.1-NuMa Interaction and Nuclear Assembly--
At least one
interaction of 4.1R CTD critical for proper reconstitution of
Xenopus nuclei appears to be NuMA binding because a 4.1R
peptide with mutations decreasing its affinity for NuMA about 60-fold
had a minor impact on nuclear assembly relative to CTD peptides with
high NuMA binding. Furthermore, the addition of NuMA Tail I peptide
containing 4.1 binding sequences severely perturbed nuclear formation.
The role of NuMA, well defined in organizing and stabilizing mitotic
spindles (47, 59-61), has remained enigmatic in nuclei. NuMA was
proposed to be a structural component of nuclei on the basis of its
association with nuclear matrix (62-64), its localization on a subset
of nuclear filaments (63), and its capacity to form ordered lattices
during overexpression (65, 66). Formation of micronuclei after NuMA
antibody microinjection or overexpression suggested that NuMA plays a
role in nuclear assembly after mitosis (61, 67, 68). However, NuMA may
be nonessential for nuclear structure because nuclei of several cell
types are NuMA negative, particularly certain highly differentiated
cells (47, 69). Furthermore, Merdes and Cleveland (70) reported that
Xenopus extracts depleted of NuMA by anti-NuMA form nuclei
around human sperm with apparently normal chromatin and intact nuclear
membrane structures. This finding may not be inconsistent with our
observations that 4.1CTD or NuMA Tail I peptides are deleterious to
nuclear assembly in egg extracts. First, antibody depletion of
endogenous NuMA may not exhaustively deplete NuMA-interacting proteins
present in excess, some of which may be essential for nuclear assembly. Second, NuMA Tail I peptides may have broader accessibility for binding
NuMA substrates relative to NuMA-anti-NuMA complexes. Third, 4.1R CTD
peptides might be targeting other proteins critical for nuclear
assembly that share the NuMA-binding site on protein 4.1CTD. These
possibilities will be addressed directly in future experiments
analyzing the proteins that associate with various CTD and CTD-mutated
peptides as well as with Tail I and Tail I mutant peptides.
There is now a growing roster of classically categorized cytoskeletal
structural proteins also identified in nuclei: for example, actin,
myosin, tubulin, spectrin, and 4.1R (71-75). Several of these proteins
belong to complex superfamilies. Within the 4.1 family, both the SABD
and CTD of 4.1 R and 4.1G are highly homologous, and potentially 4.1G
also could function in nuclear processes. Therefore, it will be
critical in future studies to identify family affiliations and exonic
compositions of 4.1 proteins critical for nuclear assembly. This should
aid in ultimately determining how 4.1 structural domains are
modulated for dedicated tasks in both nuclear and cytoplasmic compartments.
 |
ACKNOWLEDGEMENTS |
We thank A. Merdes for generosity in sharing
reagents and ideas. We are most grateful to M. Parra for help and
advice about 4.1 constructs and to C. Chen for technical assistance.
M. Welch and K. Weis provided valuable comments on this work. We
also thank the Heald lab and J. P. Merlie for suggestions,
experimental guidance, and good company. Roberto Couto was most helpful
in preparation of figures.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants DK32094, DK59079 (to S. W. K.), and GM57839 (to R. H.)
and funds from the Pew Scholars Program (to R. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Univ. of California,
Lawrence Berkeley National Lab., 1 Cyclotron Rd., MS 74-157, Berkeley, CA 94720. Tel.: 510-486-4073; Fax:
510-486-6746; E-mail: sakrauss@lbl.gov.
Published, JBC Papers in Press, August 8, 2002, DOI 10.1074/jbc.M204135200
2
S. W. Krauss and W. Nunomura, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
SABD, spectrin-actin-binding domain;
CTD, C-terminal domain;
PIPES, 1,4-piperazinediethanesulfonic acid;
DAPI, 4,6-diamino-2-phenylindole.
 |
REFERENCES |
| 1.
|
Conboy, J. G.
(1993)
Semin. Hematol.
30,
58-73[Medline]
[Order article via Infotrieve]
|
| 2.
|
Benz, E. J., Jr.
(1994)
in
The Molecular Basis of Blood Diseases
(Stamatoyannopoulos, G.
, Neinhuis, A. W.
, Majerus, P.
, and Varmus, H., eds), 2nd Ed.
, pp. 257-292, Saunders, Philadelphia, PA
|
| 3.
|
Mohandas, N.,
and Chasis, J. A.
(1993)
Semin. Hematol.
30,
171-192[Medline]
[Order article via Infotrieve]
|
| 4.
|
Marchesi, V. T.,
Huang, S.,
Tang, T. K.,
and Benz, E. J., Jr.
(1990)
Blood
76,
12 (abstr.)
|
| 5.
|
Correas, I.
(1991)
Biochem. J.
279,
581-585[Medline]
[Order article via Infotrieve]
|
| 6.
|
De Carcer, G.,
Lallena, M. J.,
and Correas, I.
(1995)
Biochem. J.
312,
871-877[Medline]
[Order article via Infotrieve]
|
| 7.
|
Krauss, S. W.,
Chasis, J. A.,
Larabell, C. A.,
Lockett, S.,
Gascard, P.,
Blaschke, R.,
and Mohandas, N.
(1997)
J. Cell Biol.
137,
275-289[Abstract/Free Full Text]
|
| 8.
|
Krauss, S. W.,
Chasis, J. A.,
Rogers, C.,
Mohandas, N.,
Krockmalnic, G.,
and Penman, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7297-7302[Abstract/Free Full Text]
|
| 9.
|
Mattagajasingh, S.,
Huang, S.,
Hartenstein, J.,
and Benz, E. J., Jr.
(1998)
Blood
92,
5 (abstr.)
|
| 10.
|
Conboy, J. G.,
Chan, J.,
Mohandas, N.,
and Kan, Y. W.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
9062-9065[Abstract/Free Full Text]
|
| 11.
|
Chasis, J. A.,
Coulombel, L.,
Conboy, J.,
McGee, S.,
Andrews, K.,
Kan, Y.,
and Mohandas, N.
(1993)
J. Clin. Invest.
91,
329-338[Medline]
[Order article via Infotrieve]
|
| 12.
|
Horne, W. C.,
Prinz, W. C.,
and Tang, E. K.
(1990)
Biochim. Biophys. Acta
1055,
87-92[Medline]
[Order article via Infotrieve]
|
| 13.
|
Huang, J. P.,
Tang, C. J.,
Kou, G. H.,
Marchesi, V. T.,
Benz, E. J., Jr.,
and Tang, T. K.
(1993)
J. Biol. Chem.
268,
3758-3766[Abstract/Free Full Text]
|
| 14.
|
Subrahmanyam, G.,
Bertics, P. J.,
and Anderson, R. A.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
5222-5226[Abstract/Free Full Text]
|
| 15.
|
Cohen, C.,
and Foley, S.
(1984)
Biochemistry
23,
6091-6098[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Discher, D. E.,
Parra, M.,
Conboy, J. G.,
and Mohandas, N.
(1993)
J. Biol. Chem.
268,
7186-7195[Abstract/Free Full Text]
|
| 17.
|
Morris, M. B.,
Ralston, G. B.,
Biden, T. J.,
Browne, C. L.,
King, G. F.,
and Iismaa, T. P.
(1995)
Biochemistry
34,
4538-4545[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Ohanian, V.,
and Gratzer, W.
(1984)
Eur. J. Biochem.
144,
375-379[Medline]
[Order article via Infotrieve]
|
| 19.
|
Schischmanoff, P. O.,
Winardi, R.,
Discher, D. E.,
Parra, M. K.,
Bicknese, S. E.,
Witkowska, H. E.,
Conboy, J. G.,
and Mohandas, N.
(1995)
J. Biol. Chem.
270,
21243-21250[Abstract/Free Full Text]
|
| 20.
|
Takakuwa, Y.,
Tchernia, G.,
Rossi, M.,
Benabadji, M.,
and Mohandas, N.
(1986)
J. Clin. Invest.
78,
80-85[Medline]
[Order article via Infotrieve]
|
| 21.
|
Ungewickell, E.,
Bennett, P. M.,
Calvert, R.,
Ohanian, V.,
and Gratzer, W. B.
(1979)
Nature
280,
811-814[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Nunomura, W.,
Takakuwa, Y.,
Parra, M.,
Conboy, J. G.,
and Mohandas, N.
(2000)
J. Biol. Chem.
275,
6360-6367[Abstract/Free Full Text]
|
| 23.
|
Nunomura, W.,
Takakuwa, Y.,
Tokimitsu, R.,
Krauss, S. W.,
Kawashima, M.,
and Mohandas, N.
(1997)
J. Biol. Chem.
272,
30322-30328[Abstract/Free Full Text]
|
| 24.
|
Han, B. G.,
Nunomura, W.,
Takakuwa, Y.,
Mohandas, N.,
and Jap, B. K.
(2000)
Nat. Struct. Biol.
7,
871-875[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Gascard, P.,
and Mohandas, N.
(2000)
Curr. Opin. Hematol.
7,
123-129[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Gascard, P.,
Nunomura, W.,
Lee, G.,
Walensky, L.,
Krauss, S.,
Chasis, J.,
Mohandas, N.,
and Conboy, J.
(1999)
Mol. Biol. Cell
10,
1783-1798[Abstract/Free Full Text]
|
| 27.
|
Mattagajasingh, S. N.,
Huang, S. C.,
Hartenstein, J. S.,
Snyder, M.,
Marchesi, V. T.,
and Benz, E. J., Jr.
(1999)
J. Cell Biol.
145,
29-43[Abstract/Free Full Text]
|
| 28.
|
Mattagajasingh, S. N.,
Huang, S. C.,
Hartenstein, J. S.,
and Benz, E. J., Jr.
(2000)
J. Biol. Chem.
275,
30573-30585[Abstract/Free Full Text]
|
| 29.
|
Walensky, L. D.,
Gascard, P.,
Fields, M. E.,
Blackshaw, S.,
Conboy, J. G.,
Mohandas, N.,
and Snyder, S. H.
(1998)
J. Cell Biol.
141,
143-153[Abstract/Free Full Text]
|
| 30.
|
Sawin, K. E.,
and Mitchison, T. J.
(1991)
J. Cell Biol.
112,
941-954[Abstract/Free Full Text]
|
| 31.
|
Sawin, K. E.,
and Mitchison, T. J.
(1991)
J. Cell Biol.
112,
925-940[Abstract/Free Full Text]
|
| 32.
|
Shamu, C. E.,
and Murray, A. W.
(1992)
J. Cell Biol.
117,
921-934[Abstract/Free Full Text]
|
| 33.
|
Murray, A. W.,
and Kirschner, M. W.
(1989)
Nature
339,
280-286[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Murray, A. W.,
and Kirschner, M. W.
(1989)
Nature
339,
275-280[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Lohka, M. J.,
and Maller, J. L.
(1985)
J. Cell Biol.
101,
518-523[Abstract/Free Full Text]
|
| 36.
|
Murray, A.
(1991)
Methods Cell Biol.
36,
581-605[Medline]
[Order article via Infotrieve]
|
| 37.
|
Hyman, A.,
Drechsel, D.,
Kellogg, D.,
Salser, S.,
Sawin, K.,
Steffen, P.,
Wordeman, L.,
and Mitchison, T.
(1991)
Methods Enzymol.
196,
478-485[Medline]
[Order article via Infotrieve]
|
| 38.
|
Heald, R.,
Tournebize, R.,
Habermann, A.,
Karsenti, E.,
and Hyman, A.
(1997)
J. Cell Biol.
138,
615-628[Abstract/Free Full Text]
|
| 39.
|
Nunomura, W.,
Takakuwa, Y.,
Parra, M.,
Conboy, J.,
and Mohandas, N.
(2000)
J. Biol. Chem.
275,
24540-24546[Abstract/Free Full Text]
|
| 40.
|
Winardi, R.,
Discher, D.,
Kelley, C.,
Zon, L.,
Mays, K.,
Mohandas, N.,
and Conboy, J. G.
(1995)
Blood
86,
4315-4322[Abstract/Free Full Text]
|
| 41.
|
Krauss, S.,
Heald, R.,
Lee, G.,
Berger, T.,
and Chasis, J.
(1998)
Mol. Biol. Cell
9,
294 (abstr.)
|
| 42.
|
Lallena, M. J.,
Martinez, C.,
Valcarcel, J.,
and Correas, I.
(1998)
J. Cell Sci.
111,
1963-1971[Medline]
[Order article via Infotrieve]
|
| 43.
|
Lallena, M. J.,
and Correas, I.
(1997)
J. Cell Sci.
110,
239-247[Abstract]
|
| 44.
|
Mintz, P. J.,
and Spector, D. L.
(2000)
J. Struct. Biol.
129,
241-251[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Gimm, J. A., An X. L.,
Nunomura, W.,
and Mohandas, N.
(2002)
Biochemistry
41,
7275-7282[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Mattagajasingh, S.,
Huang, S.,
and Benz, E., Jr.
(1997)
Blood
90,
408 (abstr.)
|
| 47.
|
Merdes, A.,
Ramyar, K.,
Vechio, J. D.,
and Cleveland, D. W.
(1996)
Cell
87,
447-458[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Gant, T. M.,
and Wilson, K. L.
(1997)
Annu. Rev. Cell Dev. Biol.
13,
669-695[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Newport, J.
(1987)
Cell
48,
205-217[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Spann, T. P.,
Moir, R. D.,
Goldman, A. E.,
Stick, R.,
and Goldman, R. D.
(1997)
J. Cell Biol.
136,
1201-1212[Abstract/Free Full Text]
|
| 51.
|
Schirmer, E. C.,
Guan, T.,
and Gerace, L.
(2001)
J. Cell Biol.
153,
479-489[Abstract/Free Full Text]
|
| 52.
|
Newport, J. W.,
Wilson, K. L.,
and Dunphy, W. G.
(1990)
J. Cell Biol.
111,
2247-2259[Abstract/Free Full Text]
|
| 53.
|
Correas, I.,
Leto, T. L.,
Speicher, D. W.,
and Marchesi, V. T.
(1986)
J. Biol. Chem.
261,
3310-3315[Abstract/Free Full Text]
|
| 54.
|
Correas, I.,
Speicher, D. W.,
and Marchesi, V. T.
(1986)
J. Biol. Chem.
261,
13362-13366[Abstract/Free Full Text]
|
| 55.
|
Rando, O. J.,
Zhao, K.,
and Crabtree, G. R.
(2000)
Trends Cell Biol.
10,
92-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Zhao, K.,
Wang, W.,
Rando, O. J.,
Xue, Y.,
Swiderek, K.,
Kuo, A.,
and Crabtree, G. R.
(1998)
Cell
95,
625-636[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Zhang, S.,
Buder, K.,
Burkhardt, C.,
Schlott, B.,
Gorlach, M.,
and Grosse, F.
(2002)
J. Biol. Chem.
277,
843-853[Abstract/Free Full Text]
|
| 58.
|
Sahlas, D. J.,
Milankov, K.,
Park, P. C.,
and De Boni, U.
(1993)
J. Cell Sci.
105,
347-357[Abstract]
|
| 59.
|
Gaglio, T.,
Saredi, A.,
and Compton, D. A.
(1995)
J. Cell Biol.
131,
693-708[Abstract/Free Full Text]
|
| 60.
|
Merdes, A.,
Heald, R.,
Samejima, K.,
Earnshaw, W. C.,
and Cleveland, D. W.
(2000)
J. Cell Biol.
149,
851-862[Abstract/Free Full Text]
|
| 61.
|
Price, C. M.,
and Pettijohn, D. E.
(1986)
Exp. Cell Res.
166,
295-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Zeng, C., He, D.,
Berget, S. M.,
and Brinkley, B. R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1505-1509[Abstract/Free Full Text]
|
| 63.
|
Zeng, C., He, D.,
and Brinkley, B. R.
(1994)
Cell Motil. Cytoskel.
29,
167-176[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Kallajoki, M.,
Weber, K.,
and Osborn, M.
(1991)
EMBO J.
10,
3351-3362[Medline]
[Order article via Infotrieve]
|
| 65.
|
Zeng, C.
(2000)
Microsc. Res. Tech.
49,
467-477[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Gueth-Hallonet, C.,
Wang, J.,
Harborth, J.,
Weber, K.,
and Osborn, M.
(1998)
Exp. Cell Res.
243,
434-452[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Compton, D. A.,
and Cleveland, D. W.
(1993)
J. Cell Biol.
120,
947-957[Abstract/Free Full Text]
|
| 68.
|
Compton, D. A.,
and Cleveland, D. W.
(1994)
Curr. Opin. Cell Biol.
6,
343-346[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Taimen, P.,
Viljamaa, M.,
and Kallajoki, M.
(2000)
Exp. Cell Res.
256,
140-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 70.
|
Merdes, A.,
and Cleveland, D. W.
(1998)
J. Cell Sci.
111,
71-79[Abstract]
|
| 71.
|
Nowak, G.,
Pestic-Dragovich, L.,
Hozak, P.,
Philimonenko, A.,
Simerly, C.,
Schatten, G.,
and de Lanerolle, P.
(1997)
J. Biol. Chem.
272,
17176-17181[Abstract/Free Full Text]
|
| 72.
|
Milankov, K.,
and DeBoni, U.
(1993)
Exp. Cell Res.
209,
189-199[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Tse, W. T.,
Tang, J.,
Jin, O.,
Korsgren, C.,
John, K. M.,
Kung, A. L.,
Gwynn, B.,
Peters, L. L.,
and Lux, S. E.
(2001)
J. Biol. Chem.
276,
23974-23985[Abstract/Free Full Text]
|
| 74.
|
Woulfe, J.,
and Munoz, D.
(2000)
Neuropathol. Appl. Neurobiol.
26,
161-171[CrossRef][Medline]
[Order article via Infotrieve]
|
| 75.
|
Smrzka, O. W.,
Delgehyr, N.,
and Bornens, M.
(2000)
Curr. Biol.
10,
413-416[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Parra, M.,
Gascard, P.,
Walensky, L. D.,
Snyder, S. H.,
Mohandas, N.,
and Conboy, J. G.
(1998)
Genomics
49,
298-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 77.
|
Parra, M.,
Gascard, P.,
Walensky, L. D.,
Gimm, J. A.,
Blackshaw, S.,
Chan, N.,
Takakuwa, Y.,
Berger, T.,
Lee, G.,
Chasis, J. A.,
Snyder, S. H.,
Mohandas, N.,
and Conboy, J. G.
(2000)
J. Biol. Chem.
275,
3247-3255[Abstract/Free Full Text]
|
| 78.
|
Walensky, L. D.,
Blackshaw, S.,
Liao, D.,
Watkins, C. C.,
Weier, H. U.,
Parra, M.,
Huganir, R. L.,
Conboy, J. G.,
Mohandas, N.,
and Snyder, S. H.
(1999)
J. Neurosci.
19,
6457-6467[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: